

**Questionnaire**  
**Combination Products (CP)**  
**(Draft)**

Please tick appropriate boxes ☒ and indicate your comment/statement and return to Dr. Ming-Che Wang at [mcwang@cde.org.tw](mailto:mcwang@cde.org.tw) at your earliest convenience.

First Name		
Last Name		
Title	Mr. Mrs. Ms. Dr. Other_____ <b>(Please circle one)</b>	
Member Economy		
Position		
Company/Organization		
<b>Questions</b>	<b>Comment/Statement</b>	
Regulation of Combination Products (CP) has been implemented?	Yes <input type="checkbox"/> _____	No <input type="checkbox"/> _____
Guidance or Guidelines implemented for CP?	Yes <input type="checkbox"/> _____	No <input type="checkbox"/> _____
Definition of CP		
Components of CP		
Combination methods of CP		
Agency review determinations - who is the lead?		

Pre-market review route of CP submissions?		
Agency “non-primary” component consultations		
Are separate applications required for different components of investigational applications (clinical study) for CP?	Yes <input type="checkbox"/> _____	No <input type="checkbox"/> _____
Are separate applications required for different components of CP applications?	Yes <input type="checkbox"/> _____	No <input type="checkbox"/> _____
GMP/QS requirements for CP?		
Adverse events/Vigilance Reporting Requirements for CP?		
Registration and Listing requirements for CP?		
Other CP Initiatives?		